Lantheus Holdings (LNTH) said Monday it has agreed to acquire Life Healthcare Group subsidiary Life Molecular Imaging in an all-cash deal worth up to $750 million.
The consideration consists of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments. Lantheus Radiopharmaceuticals UK, a unit of Lantheus, may pay up to $30 million toward Life Medical Group's retained future contingent liabilities, subject to certain contract arrangements.
The deal is expected to complete in H2 2025, subject to clearance from regulators and approval from Life Healthcare's shareholders.
Lantheus expects the deal to be accretive to adjusted per-share earnings within 12 months of completion.
The company anticipates that the acquisition will strengthen its growth profile with the addition of Neuraceq, a diagnostic agent to detect beta-amyloid plaques in patients with Alzheimer's Disease.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。